European, UK drug regulators warn of possible dangerous interaction between clopidogrel and PPIs.
2009-06-24
The European Medicines Agency (EMEA) has now issued a public statement on a possible interaction between clopidogrel (Plavix) and proton-pump inhibitors (PPIs) and has recommended that the product information for all clopidogrel-containing medicines be amended to discourage concomitant use of PPIs unless absolutely necessary." The UK drug regulator, called the "Medicines and Healthcare Products Regulatory Agency (MHRA), has also issued advice to GPs that concomitant use of a PPI with clopidogrel is not recommended unless considered essential, urging a review of the prescribing